Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus

Table 1 Patient characteristics, IFN-γ enzyme-linked immunosorbent spot, and serum HBV DNA levels of children with successful prophylactic treatment and their mothers.

Patient ID*	Age (years)	Gender	Levels of serum hepatitis B surface antibodies (mIU/mL)	Hepatitis B e antigen status	Hepatitis B core antibody status	Levels of serum ALT (IU/L)	† core 117-125 (spots/10⁶ PBMCs)	† pol 756-764 (spots/10⁶ PBMCs)	Levels of serum hepatitis B virus DNA (copies/mL)
M1	22			Pos	Pos	18	14.1	17.6	> 10^8.8
C1	2	Female	84.7		Neg	16	0	5.0	100
M2	28			Neg	Pos	13	0	0	10^4.0
C2	2	Male	40.6		Neg	17	0	8.9	80
M3	43			Neg	Pos	10	4.5	0.9	10^3.2
C3a	11	Female	16.2		Neg	8	0	6.5	Neg
C3b	6	Male	172.1		Pos	17	0	0	Neg
M4	32			Neg	Pos	11	30.8	47.3	10^3.1
C4	6	Male	28.2		Neg	15	13.9	94.4	Neg
M5	34			Neg	Pos	37	0	0	10^3.0
C5a	8	Female	118.9		Neg	20	12.5	0	Neg
C5b	6	Female	63.4		Neg	13	68.0	114.3	80
M6	32			Neg	Pos	17	48.2	8.2	10^3.7
C6a	6	Female	6.3		Neg	11	0	0	Neg
C6b	4	Female	<5		Neg	12	40.0	0	Neg
C6c	2	Male	<5		Neg	11	2.9	29.4	Neg
M7	40			Pos	Pos	14	9.8	18.5	10^8.1
C7a	13	Male	<5		Neg	18	0	0	Neg
C7b	4	Female	34.2		Neg	11	0	0	Neg
M8	22			Neg	Pos	15	0	0	10^4.3
C8	0	Male	252.9		Pos	17	29.1	0	80

* M and C indicate mother and child, respectively. Number indicates family ID. † More than 50 spots/10⁶ PBMCs were defined as a significant HBV-specific T-cell response. PBMCs, peripheral blood mononuclear cells. Pos, positive Neg, negative

ISSN: 1471-2334